Author
University of North Carolina at Chapel HillORCID 0000-0002-5983-9439Unclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp…·Bjoern Papke
This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.
Wen-Hsuan Chang, Alec J. Vaughan, Addison G. Stamey…·Channing J. Der
This study identifies KEAP1 loss as a resistance mechanism to KRAS inhibitors in pancreatic and lung cancer and shows that combining glutamine inhibition with KRAS inhibitors can overcome this resistance.
Kristina Drizyte‐Miller, Seamus E. Degan, Ryan D. Mouery…·Channing J. Der
This study shows that ONC201 inhibits KRAS-mutant pancreatic cancer growth and overcomes resistance to RAS inhibitors by activating ClpP and altering metabolic pathways.